Finance

Beta
Lists
1HALO:BIT
Halozyme Therapeutics, Inc.
€58.52
+2.27%
(+1.30) 1D
May 19, 4:13:57 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for 1HALO...
Mkt. cap
8.28B
Avg. vol.
3.00
Volume
0.00
52-wk high
€69.82
52-wk low
€44.51
No. of employees
423
Mkt. cap
8.28B
Avg. vol.
3.00
Volume
0.00
52-wk high
€69.82
52-wk low
€44.51
No. of employees
423
News stories
From sources across the web
Profile
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment. The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California. Wikipedia
About Halozyme Therapeutics, Inc.
CEOHelen I. Torley
Employees423
Founded1998
HeadquartersSan Diego, California, United States
SectorBiotechnology
Websitehalozyme.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
325.72M
354.26M
451.77M
376.71M
Cost of goods sold
63.90M
72.49M
110.67M
104.80M
Cost of revenue
63.90M
72.49M
110.67M
104.80M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
41.61M
46.09M
63.33M
57.88M
Operating expense
59.38M
63.85M
86.70M
87.39M
Total operating expenses
123.28M
136.34M
197.37M
192.19M
Operating income
202.44M
217.92M
254.40M
184.52M
Other non operating income
6.89M
-
-
-
EBT including unusual items
204.94M
218.96M
-100.85M
180.33M
EBT excluding unusual items
204.94M
218.96M
251.58M
180.30M
Income tax expense
39.78M
43.73M
40.74M
30.28M
Effective tax rate
19.41%
19.97%
-40.40%
16.79%
Other operating expenses
-
-
-
-
Net income
165.16M
175.22M
-141.59M
150.05M
Net profit margin
50.71%
49.46%
-31.34%
39.83%
Earnings per share
1.54
1.72
-0.24
1.60
Interest and investment income
-
5.33M
2.09M
1.29M
Interest expense
-4.39M
-4.30M
-4.91M
-5.51M
Net interest expenses
-4.39M
1.04M
-2.82M
-4.22M
Depreciation and amortization charges
-
-
-
-
EBITDA
221.44M
236.84M
279.08M
215.65M
Gain or loss from assets sale
-
-
2.62M
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer